Lempo Therapeutics

Company Overview

Snapshot

Founded in December 2017 by Oren Glanz and Prof. Ben-Zion Garty, Lempo Therapeutics operates with 1–10 employees. The company is in the Pre-Funding stage, focusing on developing gene-editing solutions for chronic diseases.

Business overview

Lempo Therapeutics is a preclinical biotech company specializing in gene editing to modulate the immune system, aiming to attenuate severe chronic diseases. The company's core technology involves a patented ex vivo stem cell gene-editing technique designed to minimize immune system-induced collateral damage and mitigate disease progression. Initially targeting pulmonary arterial hypertension (PAH), a severe cardiovascular disease, their concept has demonstrated efficacy in animal models for various conditions including Alzheimer's disease, multiple sclerosis, and other cardiovascular diseases. Lempo Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, focusing on drugs discovery and development.

Company Intelligence Q&A

What is Lempo Therapeutics' primary focus?

Lempo Therapeutics is focused on developing gene-editing solutions to modify the immune system for the attenuation of severe chronic diseases, with an initial focus on pulmonary arterial hypertension (PAH).

When was Lempo Therapeutics founded?

Lempo Therapeutics was founded in December 2017.

Who are the founders of Lempo Therapeutics?

Lempo Therapeutics was co-founded by Oren Glanz and Prof. Ben-Zion Garty.

What technology does Lempo Therapeutics utilize?

Lempo Therapeutics utilizes a novel, patented ex vivo stem cell gene-editing technique to minimize collateral damage from immune system activity.

What diseases has Lempo Therapeutics' concept shown efficacy in animal models for?

Lempo Therapeutics' concept has shown efficacy in animal models for Alzheimer's disease, multiple sclerosis, and cardiovascular diseases.